Previous 10 | Next 10 |
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), m...
Alzamend’s recently completed Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for ...
2023-10-30 08:34:07 ET More on Alzamend Neuro Alzamend Neuro granted extension by Nasdaq panel Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro For further detai...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder...
Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval Alzamend recently completed a Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showing a benign safety/ tolerability profile while characterizing dosing levels ...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a Section (505)(b)(2) NDA pathw...
2023-09-27 11:00:53 ET More on Alzamend Neuro Alzamend Neuro granted extension by Nasdaq panel Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro For further detai...
2023-09-22 13:42:16 ET More on Alzamend Neuro Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro For further details see: Alzamend Neuro granted extension by Nasdaq panel
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Farmer Brothers Company (FARM) is expected to report $-0.61 for Q4 2023 Aspen Group Inc. (ASPU) is expected to report for Q1 2023 Kaspien Holdings Inc. (KSPN) is expected to report for Q1 2024 AGC Inc ADR (ASGLY) is expected to report for Q2 2023 Shimano Inc. ADR (SMNNY) is expect...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...